Clinical Trials Logo

Pancreatic Ductal Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Ductal Adenocarcinoma.

Filter by:

NCT ID: NCT05303090 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab plus lenvatinib for advanced pancreatic cancer patients who were relapsed or refractory to standard therapy

NCT ID: NCT05296421 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Start date: March 14, 2022
Phase: N/A
Study type: Interventional

This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experiments done in the laboratory. These experiments may help researchers understand how cancer cells manage their nutrients when compared to normal pancreatic cells.

NCT ID: NCT05289830 Terminated - Clinical trials for Pancreatic Ductal Adenocarcinoma

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Start date: August 5, 2022
Phase: Phase 2
Study type: Interventional

Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.

NCT ID: NCT05257993 Not yet recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Start date: March 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer

NCT ID: NCT05254171 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

ASPIRE
Start date: August 8, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

NCT ID: NCT05209074 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Start date: September 8, 2022
Phase: Phase 1
Study type: Interventional

This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the neoadjuvant setting.

NCT ID: NCT05141643 Recruiting - Pancreatic Cancer Clinical Trials

Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer

Start date: November 18, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to find out whether a pre-treatment PET scan using the experimental imaging tracer 18F-FAC can show how much of the standard chemotherapy for PDAC may be taken up by the cancer.

NCT ID: NCT05132504 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Start date: August 31, 2022
Phase: Phase 2
Study type: Interventional

Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvant Trial Type: Interventional prospective Type of control: Historical Route of administration: IV Treatment Groups: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Number of trial participants: 30 Estimated enrollment period: 24 months Estimated duration of trial: 3.5 Years Duration of Participation:16 months Estimated average length of treatment per patient: 16 months

NCT ID: NCT05048810 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma

Start date: February 7, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the pharmacokinetics, dosimetry, tolerance, tumor detection rate of 68Ga-DOTA-NT-20.3 in patient with pancreatic ductal adenocarcinoma (PDAC).

NCT ID: NCT05048524 Recruiting - Pancreas Cancer Clinical Trials

Peri-operative SLOG for Localized Pancreatic Cancer

Start date: September 3, 2021
Phase: Phase 2
Study type: Interventional

1. To evaluate the efficacy of neoadjuvant chemotherapy SLOG in localized pancreatic cancer 2. To evaluate the safety profile in patients with pancreatic cancer who receive neoadjuvant SLOG 3. To collect tumor tissue and peripheral blood samples from the patients for a comprehensive biomarker evaluation